Press Releases

09Sep, 2017

Intersect ENT Announces Presentation of a Meta-Analysis from Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant

September 9th, 2017|

20Jul, 2017

Teresa L. Kline Joins Intersect ENT’s Board of Directors

July 20th, 2017|

22May, 2017

Intersect ENT Announces PDUFA Date for Office-Based SINUVA Steroid Releasing Sinus Implant

May 22nd, 2017|

08Mar, 2017

Intersect ENT Submits New Drug Application to FDA for Office-Based RESOLVE Steroid Releasing Implant for Recurrent Chronic Sinus Disease

March 8th, 2017|

24Feb, 2017

Intersect ENT Announces FDA Approval of Newest Steroid Releasing Implant, PROPEL® Contour, for Use in Treating the Frontal and Maxillary Sinuses

February 24th, 2017|

17Oct, 2016

Intersect ENT Announces Positive Clinical Results of Pivotal Study of RESOLVE In-Office Steroid Releasing Implant

October 17th, 2016|

19Sep, 2016

Intersect ENT Announces American Rhinologic Society Endorsement of the Use of Drug Eluting Sinus Implants

September 19th, 2016|

29Aug, 2016

Intersect ENT Announces Positive Coverage Decision by CareFirst BlueCross BlueShield to Expand Access to PROPEL Steroid Releasing Implants to More Patients

August 29th, 2016|

01Aug, 2016

Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease

August 1st, 2016|

11Jul, 2016

Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients with Frontal Sinus Disease

July 11th, 2016|

01Jun, 2016

Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis

June 1st, 2016|

16May, 2016

Intersect ENT Announces Positive Clinical Results from Pivotal Study of Newest Steroid Releasing Sinus Implant

May 16th, 2016|

23Mar, 2016

Intersect ENT Announces FDA Approval of Additional Indication for PROPEL® mini Sinus Implant

March 23rd, 2016|

24Feb, 2016

Intersect ENT Appoints David Lehman General Counsel

February 24th, 2016|

02Feb, 2016

Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany

February 2nd, 2016|

17Nov, 2015

Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis

November 17th, 2015|

10Nov, 2015

Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants

November 10th, 2015|

21Oct, 2015

Intersect ENT Announces Publication of Position Statement from AAO-HNS on Use of Biomaterials

October 21st, 2015|

30Sep, 2015

Intersect ENT Announces FDA Submission to Seek Expanded Indication of PROPEL Mini Steroid Releasing Implant to Treat Patients with Frontal Sinus Disease

September 30th, 2015|

28Sep, 2015

Intersect ENT Announces Positive Clinical Results from Three Studies Evaluating Steroid Releasing Implants Placed in the Physician’s Office

September 28th, 2015|

17Aug, 2015

Intersect ENT Announces Positive Preliminary Clinical Results for the PROPEL Mini Steroid Releasing Implant in Patients with Frontal Sinus Disease

August 17th, 2015|

08Jul, 2015

Intersect ENT Enrolls First Patient in Pivotal Study to Evaluate the NOVA Sinus Implant

July 8th, 2015|

08Jun, 2015

Intersect ENT Announces Exercise of Underwriters’ Option and the Closing of Its Public Offering

June 8th, 2015|

02Jun, 2015

Intersect ENT Announces Upsizing and Pricing of Public Offering

June 2nd, 2015|

04May, 2015

Intersect ENT Announces Positive Coverage Decision by Health Care Service Corporation

May 4th, 2015|

10Apr, 2015

Intersect ENT Appoints Kieran Gallahue and Tony Vernon to Board of Directors

April 10th, 2015|

29Dec, 2014

Intersect ENT Announces Enrollment of First Patient In Phase III Study of In-Office Treatment for Recurrent Chronic Sinusitis

December 29th, 2014|

24Oct, 2014

Intersect ENT Named “Fastest Growing” in San Francisco and Silicon Valley

October 24th, 2014|

08Oct, 2014

Intersect ENT Announces Publication of Positive Data from Three Studies of Company’s Drug-Eluting Sinus Implants

October 8th, 2014|

01Oct, 2014

Intersect ENT Added To Russell 2000 Index

October 1st, 2014|

22Sep, 2014

Intersect ENT Announces Positive Data from Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis

September 22nd, 2014|

17Sep, 2014

Intersect ENT Enrolls First Patient in Clinical Study to Expand Access to PROPEL Treatment to Broader Patient Population

September 17th, 2014|

11Aug, 2014

Study Indicates Cost Effectiveness of Intersect ENT’s PROPEL Implant for Chronic Sinusitis Study Author Assesses Significant Productivity Loss from Chronic Sinusitis

August 11th, 2014|

24Jul, 2014

Intersect ENT Announces Pricing of its Initial Public Offering

July 24th, 2014|

11Jul, 2014

Intersect ENT Announces Appointment of Cynthia L. Lucchese to Board of Directors

July 11th, 2014|

01Jun, 2014

Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman

June 1st, 2014|

23Jan, 2014

Intersect ENT Named One of Forbes Magazine’s “America’s Most Promising Companies” of 2014

January 23rd, 2014|

08Jan, 2014

Intersect ENT to Present at the 32nd Annual JP Morgan Healthcare Conference

January 8th, 2014|